Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Incidence, presentation and outcome of toxoplasmosis in HIV infected in the combination antiretroviral therapy era

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The efficacy of topical agents used in wounds for managing chronic biofilm infections: A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Management of MDR-TB in HIV co-infected patients in eastern europe: results from the TB:HIV study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term mortality and causes of death associated with Staphylococcus aureus bacteremia. A matched cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of neurological disorders in patients with European Lyme neuroborreliosis. A nationwide population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: HIV-associated incidence and prognosis of cerebral toxoplasmosis (CTX) is not well established during later years.

METHODS: From the Danish HIV Cohort Study, we identified 6325 HIV-infected individuals. We assessed incidence, mortality, predictive and prognostic factors of CTX during the pre-combination antiretroviral therapy (pre-cART; 1995-1996) and cART-era (1997-2014). Adjusted incidence rate ratios (aIRR), mortality rate ratios (aMRR) and 95% confidence intervals (CI) were assessed using Poisson regression analysis.

RESULTS: CTX IR was 1.17/1000 PYR (95% CI 0.93-1.47). We observed no change in CTX-risk in the first year after HIV-diagnosis, but a substantial reduction in mortality in the first 3 months after CTX diagnosis when comparing the cART-era to the pre-cART-era; {(aIRR: 0.79; 95% CI: 0.37-1.72) (aMRR: 0.15; 95% CI: 0.06-0.38)}. For individuals surviving the first year after HIV-diagnosis or the first 3 months after CTX-diagnosis, IRR and MRR had declined to minimal levels {(aIRR: 0.06; 95% CI: 0.03-0.10); (aMRR: 0.02; 95% CI: 0.01-0.05)}. Three years after CTX-diagnosis 30% of the patients still had neurological deficits.

CONCLUSION: Although, CTX remains an important cause of morbidity and mortality in the cART-era, with high prevalence of neurological sequelae, incidence and mortality has largely declined, especially among those surviving the first year after diagnosis.

OriginalsprogEngelsk
TidsskriftJournal of Infection
Vol/bind75
Udgave nummer3
Sider (fra-til)263-273
ISSN0163-4453
DOI
StatusUdgivet - 1 sep. 2017

ID: 50596551